Posted by Michael Wonder on 28 Aug 2018
Cantex Pharmaceuticals receives FDA fast track designation for CX-01 for the treatment of patients over age 60 with newly diagnosed acute myeloid leukaemia
27 August 2018 - Cantex Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for Cantex's lead product candidate, CX-01, for the treatment of patients over age 60 receiving induction therapy for newly diagnosed acute myeloid leukaemia.
Earlier this year, the FDA had also granted orphan drug designation to CX-01 for the treatment of AML.
CX-01 is currently in clinical development for newly diagnosed AML, and refractory myelodysplastic syndrome. CX-01 is designed to block the activity of chemokines that support the resistance of blood cancers to treatment and that contribute to the delay of bone marrow recovery after chemotherapy. Among these chemokines are CXCR4 and CXCL12, which are critical to the attachment of blood cancer cells to the protective bone marrow environment, and platelet factor 4, which slows bone marrow recovery after chemotherapy.
